drugset / Trial / NCT06636591

Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer

NCT06636591

Completed 14 enrolled Fudan University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

In this study, breast cancer (BC) patients eligible for inclusion will be divided into two groups according to molecular typing and subtyping, which combined immunotherapy and multimodal thermal therapy with conventional neoadjuvant chemotherapy, to explore methods of immune induction for BC, enhance the efficacy of immunotherapy, and accumulate data for subsequent stages of clinical study.

Timeline

Start
2024-12-23
Primary completion
2026-01-07
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Goserelin Other / unclassified
Background Camrelizumab Monoclonal antibody
Background Carboplatin Small molecule
Background Paclitaxel Small molecule